Impact of neoadjuvant therapy on angioplastic lobectomy: a retrospective study.

Autor:	Benkiran T; Department of Thoracic Surgery, Pasteur 1 Hospital, University Hospital of Nice, Nice, France.; University of Cote d'Azur, Nice, France., Hireche K; Department of Thoracic and Vascular Surgery, Arnaud de Villeneuve Hospital, University Hospital of Montpellier, Montpellier, France., Frey S; University of Cote d'Azur, Nice, France.; Department of General Surgical Emergency, Pasteur 2 Hospital, University Hospital of Nice, Nice, France., Morisot A; Department of Public Health, L'Archet Hospital, University Hospital of Nice, Nice, France., Nguyen A; Department of Thoracic and Vascular Surgery, Arnaud de Villeneuve Hospital, University Hospital of Montpellier, Montpellier, France., Rudondy Q; Department of Thoracic Surgery, Pasteur 1 Hospital, University Hospital of Nice, Nice, France.; University of Cote d'Azur, Nice, France., Alcaraz F; Department of Thoracic Surgery, Pasteur 1 Hospital, University Hospital of Nice, Nice, France.; University of Cote d'Azur, Nice, France., Guarino M; Department of Thoracic Surgery, Pasteur 1 Hospital, University Hospital of Nice, Nice, France.; University of Cote d'Azur, Nice, France., Cohen C; Department of Thoracic Surgery, Pasteur 1 Hospital, University Hospital of Nice, Nice, France., Gomez-Caro A; Department of Thoracic Surgery, Pasteur 1 Hospital, University Hospital of Nice, Nice, France., Berthet JP; Department of Thoracic Surgery, Pasteur 1 Hospital, University Hospital of Nice, Nice, France.; University of Cote d'Azur, Nice, France.
Jazyk:	angličtina
Zdroj:	Interdisciplinary cardiovascular and thoracic surgery [Interdiscip Cardiovasc Thorac Surg] 2024 Dec 25; Vol. 40 (1).
DOI:	10.1093/icvts/ivae191
Abstrakt:	Objectives: The efficacy of neoadjuvant therapy (NT) prior to angioplastic lobectomy (AL) in non-small cell lung cancer is unclear. This study assessed its impact on morbidity, mortality and 5-year survival. Methods: We retrospectively analysed 114 patients who underwent AL at 2 tertiary centres from January 2000 to December 2020. Comparisons were made between patients who received NT and those who did not. Results: Among the patients, 78 (68.4%) underwent upfront surgery, and 36 (31.6%) received NT. There were no significant differences in postoperative complications (46.2% vs 31.6%, P = 0.42) or mortality rates (0% vs 3.8%, P = 0.55). Pathological upstaging differed significantly (37.2% vs 5.6%, P = 0.0008). Five-year survival rates were comparable (54% vs 38%, P = 0.3). Conclusions: Neoadjuvant therapy does not adversely affect morbidity, arterial repair complications or mortality in AL. There are no survival differences at 5 years. AL remains a safe option following NT. (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu